Expert Insights: Evolving Treatment Landscape in NDMM

Opinion
Video

Panelists discuss how the treatment paradigm for newly diagnosed multiple myeloma (NDMM) has evolved from conventional chemotherapy to modern regimens incorporating novel agents like proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies while highlighting persistent challenges including optimizing treatment sequencing and addressing high-risk disease.

Video content above is prompted by the following:

  • Provide a brief historical overview of the therapeutic landscape for transplant-eligible and ineligible NDMM.
  • How has the landscape evolved since, and what challenges/unmet needs remain?
Recent Videos
5 experts in this video
Related Content
Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

Modakafusp Alfa Exhibits Antitumor Activity, Immune Activation in Myeloma

Roman Fabbricatore
March 25th 2025
Article

Modakafusp alfa induced the upregulation of the type 1 interferon gene signature score, and increased CD38 receptor density in CD-38–positive cells.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

Elotuzumab Plus PVd Displays Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
March 21st 2025
Article

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone was well tolerated in patients with relapsed/refractory multiple myeloma.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

Real-World KRd Results Comparable to Phase 3 Trial Results in Myeloma

Tim Cortese
March 14th 2025
Article

Carfilzomib, lenalidomide, and dexamethasone results from the real world continued to show effective responses and a tolerable safety profile.

Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

Handling an Intricate Case of R/R MM With BCMA/GPRC5D Bispecific Antibodies

ONCOLOGY Staff
March 9th 2025
Article

A cancer care team contemplated the methods and reasoning for handling a complex case of heavily pretreated relapsed or refractory multiple myeloma.